SAB Biotherapeutics Reports 2024 Financial Results and Advances T1D Therapy

Sab Biotherapeutics, Inc. ( (SABS) ) has released its Q4 earnings. Here is a breakdown of the information Sab Biotherapeutics, Inc. presented to its investors.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing human immunoglobulins to treat and prevent immune and autoimmune disorders, with a focus on type 1 diabetes (T1D).

SAB Biotherapeutics recently announced its financial results for the fourth quarter and full year of 2024, alongside key developments in its pipeline, notably the positive topline data from its Phase 1 trial of SAB-142, a promising therapy for T1D.

The company reported a net loss of $34.1 million for 2024, an improvement from the previous year’s loss of $42.2 million. Research and development expenses increased to $30.3 million, reflecting the company’s commitment to advancing its pipeline, while general and administrative expenses decreased to $14.0 million. The company held $20.8 million in cash and equivalents at the end of 2024.

SAB Biotherapeutics is advancing SAB-142 into a Phase 2b trial, expected to begin mid-2025, and is focused on building strategic partnerships to further its autoimmune pipeline. The company’s innovative approach using Transchromosomic Bovine™ technology positions it to address unmet medical needs without relying on human donors.

Looking ahead, SAB Biotherapeutics aims to maintain its momentum by progressing its clinical programs and forming strong development partnerships, with further data readouts anticipated in 2025.